Having trouble accessing articles? Reset your cache.

Takeda adds oncolytic viruses to pipeline via Turnstone deal

Takeda has partnered with Turnstone to discover and develop immunotherapies using the biotech’s engineered vaccinia virus platform in a deal that gives the Japanese pharma its first oncolytic virus.

Turnstone Biologics Inc. will receive upfront and near-term milestone payments and an equity investment totaling

Read the full 436 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE